Tissue Expression and Secretion of Amylin

Advances in Pharmacology

Volumn 52, Issue , 2005, Pages 19-45

  Young, Andrew ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; ANTIDIABETIC AGENT;

ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; HUMAN; METABOLISM; PANCREAS ISLET BETA CELL; REVIEW; SECRETION;

AMYLOID; ANIMALS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS;

EID: 33645216974     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(05)52002-7     Document Type: Review

References (143)

1. Ahren B., and Sundler F. Localization of calcitonin gene-related peptide and islet amyloid polypeptide in the rat and mouse pancreas. Cell Tissue Res. 269 (1992) 315-322
2. Akimoto K., Nakazato M., Matsukura S., and Hayakawa K. Plasma concentration of islet amyloid polypeptide in healthy children and patients with insulin-dependent diabetes mellitus. Acta Paediatr. 82 (1993) 310-311
3. Ardaillou R., and Paillard F. Metabolism of polypeptide hormones by the kidney. Adv. Nephrol. Necker Hosp. 9 (1980) 247-269
4. Ardaillou R., Sizonenko P., Meyrier A., Vallée G., and Beaugas C. Metabolic clearance rate of radioiodinated human calcitonin in man. J. Clin. Invest. 49 (1970) 2345-2352
5. Asai J., Nakazato M., Miyazato M., Kangawa K., Matsuo H., and Matsukura S. Regional distribution and molecular forms of rat islet amyloid polypeptide. Biochem. Biophys. Res. Commun. 169 (1990) 788-795
6. Blackard W., Clore J., Schroeder D., and Kellum J. Amylin to insulin secretory ratios in obese subjects. Diabetologia 35 (1992) A115
7. Blackard W., Clore J., Schroeder D., and Kellum J. Comparison of amylin and insulin secretory rates in obese non-diabetic man using portal vein catheterization. Diabetes 41 (1992)
8. Blackard W.G., Clore J.N., and Kellum J.M. Amylin/insulin secretory ratios in morbidly obese man: Inverse relationship with glucose disappearance rate. J. Clin. Endocrinol. Metab. 78 (1994) 1257-1260
9. Blase, E. K., Koda, J. E., and Phelps, J. L. Monoclonal antibody to the c-terminal end of human amylin-used in assays for the detection of human amylin or amylin analogues. EP 408294; WO 9211863; WO 9216845.
10. Bretherton-Watt D., Ghatei M.A., Bloom S.R., Jamal H., Ferrier G.J., Girgis S.I., and Legon S. Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes. Diabetologia 32 (1989) 881-883
11. Bretherton-Watt D., Ghatei M.A., Legon S., Jamal H., Suda K., and Bloom S.R. Depletion of islet amyloid polypeptide in the spontaneously diabetic (BB) Wistar rat. J. Mol. Endocrinol. 6 (1991) 3-7
12. Butler P.C., Chou J., Carter W.B., Wang Y.N., Bu B.H., Chang D., Chang J.K., and Rizza R.A. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39 (1990) 752-756
13. Butler P.C., Chou J., Wang Y.N., Bu B.H., Chang D., Carter B., and Rizza R. Amylin is co-secreted with insulin in man. Clin. Res. 38 (1990) 307A
14. Chou J., Butler P.C., Wang Y.N., Bu B.H., Chang D., Carter B., Rizza R., and Chang J.K. Co-secretion of amylin and insulin in the rat. Diabetes 39 (1990) 133A
15. Clodi M., Hermann K., Pacini G., Thomaseth K., Kautzky-Willer A., Prager R., and Ludvik B. Islet amyloid polypeptide distribution and kinetics in humans and its relationship to kidney function. Diabetes 45 (1996) 232A
16. Colburn W.A., Gottlieb A.B., Koda J., and Kolterman O.G. Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J. Clin. Pharmacol. 36 (1996) 13-24
17. Cooper G.J.S., Willis A.C., Clark A., Turner R.C., Sim R.B., and Reid K.B. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. USA 84 (1987) 8628-8632
18. Cooper G.J.S., Leighton B., Dimitriadis G.D., Parry-Billings M., Kowalchuk J.M., Howland K., Rothbard J.B., Willis A.C., and Reid K.B. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc. Natl. Acad. Sci. USA 85 (1988) 7763-7766
19. Culler F.L., Koda J.E., and Meacham L.R. Increased amylin secretion is a feature of glucocorticoid induced insulin resistance in man. Clin. Res. 41 (1993) 102A
20. Czyzyk A., Zapecka-Dubno B., and Kasperska-Dworak A. Metformin lowers the level of plasma amylin in patients with NIDDM. Diabetes 45 (1996) 289A
21. D'Este L., Buffa R., Pelagi M., Siccardi A.C., and Renda T. Immunohistochemical localization of chromogranin A and B in the endocrine cells of the alimentary tract of the green frog, Rana esculenta. Cell Tissue Res. 277 (1994) 341-349
22. D'Este L., Wimalawansa S.J., and Renda T.G. Amylin-immunoreactivity is co-stored in a serotonin cell subpopulation of the vertebrate stomach and duodenum. Arch. Histol. Cytol. 58 (1995) 537-547
23. De Vroede M., Foriers A., Van de Winkel M., Madsen O., and Pipeleers D. Presence of islet amyloid polypeptide in rat islet B and D cells determines parallelism and dissociation between rat pancreatic islet amyloid polypeptide and insulin content. Biochem. Biophys. Res. Commun. 182 (1992) 886-893
24. Denijn M., De Weger R.A., Van Mansfeld A.D., van Unnik J.A., and Lips C.J. Islet amyloid polypeptide (IAPP) is synthesized in the islets of Langerhans. Detection of IAPP polypeptide and IAPP mRNA by combined in situ hybridization and immunohistochemistry in rat pancreas. Histochemistry 97 (1992) 33-37
25. Dilts R.P., Phelps J., Koda J., and Beaumont K. Comparative distribution of amylin and calcitonin gene related peptide (CGRP): Immunoreactivities in the adult rat brain. Soc. Neurosci. Abstr. 21 (1995) 1116
26. Dimsdale J.E., Kolterman O., Koda J., and Nelesen R. Effect of race and hypertension on plasma amylin concentrations. Hypertension 27 (1996) 1273-1276
27. Dunning B.E., and Young D.A. Plasma and pancreatic amylin to insulin ratios are markedly elevated in obese SHR/N-cp rats. Diabetes 40 (1991) 216A
28. Edwards B.J., Perry H.M., Kaiser F.E., Morley J.E., Kraenzle D., Kreutter D.K., and Stevenson R.W. Age-related changes in amylin secretion. Mech. Ageing Dev. 86 (1996) 39-51
29. Edwards B.J.A., Perry H.M., Kaiser F.E., Morley J.E., Kraenzle D., Kreutter D., and Stevenson R. Age related changes in amylin secretion. Clin. Res. 40 (1992) 197A
30. Enoki S., Mitsukawa T., Takemura J., Nakazato M., Aburaya J., Toshimori H., and Matsukara S. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabet. Res. Clin. Pract. 15 (1992) 97-102
31. Eriksson J., Nakazato M., Miyazato M., Shiomi K., Matsukura S., and Groop L. Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35 (1992) 291-293
32. Ferrannini E., Haffner S.M., and Stern M.P. Essential hypertension-an insulin-resistant state. J. Cardiovasc. Pharmacol. 15 (1990) S18-S25
33. Fineman M.S., Koda J.E., Percy A., Wareham N.J., and Hales C.N. Elevation of high molecular weight amylin-like peptides along with proinsulin and 32,33 split proinsulin in newly diagnosed diabetics. Diabetologia 37 (1994) A52
34. ® ingestion is diminished in type II diabetic patients treated with insulin. Diabetologia 39 (1996) A149
35. Foster G.V., Clark M.B., Williams C., Nathanson B.M., Horton R., Buranapong P., and Glass H.I. Metabolic fate of human calcitonin in the dog. In: Taylor S. (Ed). "Endocrinology 1971" (1972), Heinemann Books, London 72-78
36. Gilbey S.G., Ghatei M.A., Bretherton-Watt D., Zaidi M., Jones P.M., Perera T., Beacham J., Girgis S., and Bloom S.R. Islet amyloid polypeptide: Production by an osteoblast cell line and possible role as a paracrine regulator of osteoclast function in man. Clin. Sci. (Colch) 81 (1991) 803-808
37. Gill A.M., and Yen T.T. Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice. Life Sci. 48 (1991) 703-710
38. Hammonds P., Palmieri L., Troge J., and Mertz R. Co-ordinate regulation of insulin and amylin secretion from rat islets of Langerhans and HIT-T15 β-cells. J. Cell Biochem. 15B (1991) 66
39. Hanabusa T., Kubo K., Oki C., Nakano Y., Okai K., Sanke T., and Nanjo K. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus. Diabet. Res. Clin. Pract. 15 (1992) 89-96
40. Hartter E., Svoboda T., Ludvik B., Schuller M., Lell B., Kuenburg E., Brunnbauer M., Woloszczuk W., and Prager R. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34 (1991) 52-54
41. Hiles R.A., Bawdon R.E., and Petrella E. An evaluation of the potential of two peptides, pramlintide and AC2993 (synthetic exendin-4), to cross the human placental barrier using an ex vivo perfusion system. Toxicologist 66 (2002) 237
42. Hiles R.A., Bawdon R.E., and Petrella E.M. Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4). Hum. Exp. Toxicol. 22 (2003) 623-628
43. Hiramatsu S., Inoue K., Sako Y., Umeda F., and Nawata H. Insulin treatment improves relative hypersecretion of amylin to insulin in rats with non-insulin-dependent diabetes mellitus induced by neonatal streptozocin injection. Metabolism 43 (1994) 766-770
44. Huang H.-J.S., Cooper G.J.S., Young A.A., and Johnson M.J. Deficiency of amylin expression in the pancreas of auto-immune BB/Wor diabetic rats. J. Cell Biochem. 15 Part B (1991) 67
45. Huang H.-J.S., Young A.A., Johnson J.M., Gedulin B., and Cooper G.J.S. Amylin mRNA in the autoimmune diabetic BB/Wor and insulin-resistant LA/N-cp rat. Diabetes 40 (1991) 46A
46. Huang H.-J.S., Young A.A., Koda J.E., Tulp O.L., Johnson M.J., and Cooper G.J. Hyperamylinemia, hyperinsulinemia, and insulin resistance in genetically obese LA/N-cp rats. Hypertension 19 (1992) I101-I109
47. Inman L., LeChago J., Roitelman Y., and Luskey K. Pancreatic beta cell expression of amylin in streptozotocin-induced diabetes in rats. Diabetes 39 (1990) 143A
48. Jamal H., Bretherton-Watt D., Suda K., Ghatei M.A., and Bloom S.R. Islet amyloid polypeptide-like immunoreactivity (amylin) in rats treated with dexamethasone and streptozotocin. J. Endocrinol. 126 (1990) 425-429
49. Jamal H., Bretherton-Watt D., Suda K., Wang Z.L., Ghatei M.A., Williams S., and Bloom S.R. Changes in islet peptide content after dexamethasone treatment. J. Endocrinol. 129 (1991) 93
50. Jamal H., Suda K., Bretherton-Watt D., Ghatei M.A., and Bloom S.R. Molecular form of islet amyloid polypeptide (amylin) released from isolated rat islets of Langerhans. Pancreas 8 (1993) 261-266
51. Johnson K.H., O'Brien T.D., Hayden D.W., Jordan K., Ghobrial H.K., Mahoney W.C., and Westermark P. Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am. J. Pathol. 130 (1988) 1-8
52. Jorde R., Burhol P.G., Gunnes P., and Schulz T.B. Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats. Scand. J. Gastroenterol. 16 (1981) 469-471
53. Kailasam M.T., Fineman M.S., Koda J.E., Parmer R.J., and O'Connor D.T. Circulating amylin in human essential hypertension: Racial differences and early elevations in subjects at genetic risk of hypertension. J. Investig. Med. 43 (1995) 266A
54. Kanatsuka A., Makino H., Ohsawa H., Tokuyama Y., Yamaguchi T., Yoshida S., and Adachi M. Secretion of islet amyloid polypeptide in response to glucose. FEBS Lett. 259 (1989) 199-201
55. Kautzky-Willer A., Thomaseth K., Pacini G., Clodi M., Ludvik B., Streli C., Waldhausl W., and Prager R. Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 37 (1994) 188-194
56. Kautzky-Willer A., Thomaseth K., Clodi M., Ludvik B., Waldhausl W., Prager R., and Pacini G. Beta-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects. Metab. Clin. Exp. 45 (1996) 486-491
57. Kautzky-Willer A., Thomaseth K., Nowotny P., Ludvik B., Waldhäusl W., and Prager R. Elevated proinsulin and islet amyloid pancreatic polypeptide (IAPP) secretion in gestational diabetes. Diabetes 45 (1996) 174A
58. Koda J., Fineman M., Percy A., Blase E., and Lillioja S. Use of a new two-site immunoassay for amylin to characterize amylin hormone response in Pima Indians. Diabetologia 36 (1993) A137
59. Koda J.E., Fineman M., Rink T.J., Dailey G.E., Muchmore D.B., and Linarelli L.G. Amylin concentrations and glucose control. Lancet 339 (1992) 1179-1180
60. Koda J.E., Fineman M.S., Kolterman O.G., and Caro J.F. 24 hour plasma amylin profiles are elevated in IGT subjects vs. normal controls. Diabetes 44 suppl. 1 (1995) 238A
61. Koda J.E., Nyholm B., Fineman M.S., Hove K.Y., and Schmitz O. Plasma concentrations of amylin reflect insulin sensitivity in relatives of patients with NIDDM and in healthy subjects. Diabetologia 39 (1996) A68
62. Koranyi L., Bourey R., Turk J., Mueckler M., and Permutt M.A. Differential expression of rat pancreatic islet beta-cell glucose transporter (GLUT 2), proinsulin and islet amyloid polypeptide genes after prolonged fasting, insulin-induced hypoglycaemia and dexamethasone treatment. Diabetologia 35 (1992) 1125-1132
63. Leffert J.D., Chick W.L., and Luskey K.L. Islet specific expression of rat amylin. Clin. Res. 37 (1989) 571A
64. Leighton B., Chantry A., and Foot E.A. Skeletal muscle may be a site for degradation of CGRP and possibly amylin. Diabetologia 35 (1992) A18
65. Li Z., Shi A., and Karlsson F.A. Transient increase of rat gastric amylin in the neonatal period and in experimental ulcers. J. Gastroenterol. 37 (2002) 172-176
66. Ludvik B., Berzlanovich A., Hartter E., Lell B., Prager R., and Graf H. Increased amylin levels in patients on chronic hemodialysis. Nephrol. Dial. Transplant. 5 (1990) 694-695
67. Ludvik B., Lell B., Hartter E., Schnack C., and Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 40 (1991) 1615-1619
68. Ludvik B., Clodi M., Kautzky-Willer A., Capek M., Hartter E., Pacini G., and Prager R. Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia 36 (1993) 84-87
69. Ludvik B., Clodi M., Kautzky-Willer A., Schuller M., Graf H., Hartter E., Pacini G., and Prager R. Increased levels of circulating islet amyloid polypeptide in patients with chronic renal failure have no effect on insulin secretion. J. Clin. Invest. 94 (1994) 2045-2050
70. Ludvik B., Nolan J.J., Thomaseth K., Pacini G., Clodi M., and Prager R. Direct assessment of secretion, kinetics and clearance of beta-cell peptides during hepatic vein catheterization. Diabetes 45 (1996) 253A
71. Lukinius A., Wilander E., Westermark G.T., Engstrom U., and Westermark P. Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 32 (1989) 240-244
72. Lukinius A., Korsgren O., Grimelius L., and Wilander E. Expression of islet amyloid polypeptide in fetal and adult porcine and human pancreatic islet cells. Endocrinology 137 (1996) 5319-5325
73. Lutz T.A., and Rand J.S. Detection of amyloid deposition in various regions of the feline pancreas by different staining techniques. J. Comp. Pathol. 116 (1997) 157-170
74. Manley S., and Hales C.N. Interim report from an international workshop for the comparison of amylin assays. Diabetes 46 (1997) 344A
75. Mitsukawa T., Takemura J., Asai J., Nakazato M., Kangawa K., Matsuo H., and Matsukura S. Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes 39 (1990) 639-642
76. Mitsukawa T., Toshimori H., Nakazato M., Takemura J., and Matsukura S. A study of serial plasma islet amyloid polypeptide IAPP levels in an obese NIDDM patient associated with diabetic ketoacidosis. J. Jpn. Diabet. Soc. 34 (1991) 543-548
77. Mitsukawa T., Takemura J., Nakazato M., Asai J., Kanagawa K., Matsuo H., and Matsukura S. Effects of aging on plasma islet amyloid polypeptide basal level and response to oral glucose load. Diabet. Res. Clin. Pract. 15 (1992) 131-134
78. Miyazato M., Nakazato M., Shiomi K., Aburaya J., Toshimori H., Kangawa K., Matsuo H., and Matsukura S. Identification and characterization of islet amyloid polypeptide in mammalian gastrointestinal tract. Biochem. Biophys. Res. Commun. 181 (1991) 293-300
79. Moyses C., Kolterman O., and Mant T. Pharmacokinetics and hyperglycaemic effects of the amylin analogue, AC137, in man. Diabet. Med. 10 (1993) S25
80. Mulder H., Lindh A.C., and Sundler F. Islet amyloid polypeptide gene expression in the endocrine pancreas of the rat-a combined in situ hybridization and immunocytochemical study. Cell Tissue Res. 274 (1993) 467-474
81. Mulder H., Lindh A.C., Ekblad E., Westermark P., and Sundler F. Islet amyloid polypeptide is expressed in endocrine cells of the gastric mucosa in the rat and mouse. Gastroenterology 107 (1994) 712-719
82. Mulder H., Ahren B., Stridsberg M., and Sundler F. Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. Diabetologia 38 (1995) 395-402
83. Mulder H., Ahren B., and Sundler F. Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents. Mol. Cell Endocrinol. 114 (1995) 101-109
84. Mulder H., Leckstrom A., Uddman R., Ekblad E., Westermark P., and Sundler F. Islet amyloid polypeptide (amylin) is expressed in sensory neurons. J. Neurosci 15 (1995) 7625-7632
85. Mulder H., Ahren B., and Sundler F. Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats. Diabetologia 39 (1996) 649-657
86. Mulder H., Ahren B., and Sundler F. Islet amyloid polypeptide and insulin gene expression are regulated in parallel by glucose in vivo in rats. Am. J. Physiol. 271 (1996) E1008-E1014
87. Mulder H., Myrsen U., Ahren B., and Sundler F. Differential expression of islet amyloid polypeptide and insulin correlates with the severity of experimental diabetes. Diabetes 45 (1996) 292A
88. Mulder H., Ekelund M., Ekblad E., and Sundler F. Islet amyloid polypeptide in the gut and pancreas: Localization, ontogeny and gut motility effects. Peptides 18 (1997) 771-783
89. Mulder H., Zhang Y.Z., Danielsen N., and Sundler F. Islet amyloid polypeptide and calcitonin gene-related peptide expression are down-regulated in dorsal root ganglia upon sciatic nerve transection. Mol. Brain Res. 47 (1997) 322-330
90. Nakazato M., Asai J., Kangawa K., Matsukura S., and Matsuo H. Establishment of radioimmunoassay for human islet amyloid polypeptide and its tissue content and plasma concentration. Biochem. Biophys. Res. Commun. 164 (1989) 394-399
91. Nakazato M., Miyazato M., Asai J., Mitsukawa T., Kangawa K., Matsuo H., and Matsukura S. Islet amyloid polypeptide, a novel pancreatic peptide, is a circulating hormone secreted under glucose stimulation. Biochem. Biophys. Res. Commun. 169 (1990) 713-718
92. Nicholl C.G., Bhatavdekar J.M., Mak J., Girgis S.I., and Legon S. Extra-pancreatic expression of the rat islet amyloid polypeptide (amylin) gene. J. Mol. Endocrinol. 9 (1992) 157-163
93. Nieuwenhuis M.G., van Hulst K.L., Hackeng W.H.L., and Lips C.J.M. Islet amyloid polypeptide plasma concentrations in patients with insulinoma. Diabetologia 35 (1992) A119
94. Nieuwenhuis M.G., van Mansfeld A.D., van Unnik J.A., Berends M.J., and Lips C.J. No constant relationship between islet amyloid polypeptide (IAPP) and insulin expression in insulinomas. Neth. J. Med. 41 (1992) 264-271
95. Nishimura S., Sanke T., Machida K., Bessho H., Hanabusa T., Nakai K., and Nanjo K. Lack of effect of islet amyloid polypeptide on hepatic glucose output in the in situ-perfused rat liver. Metabolism 41 (1992) 431-434
96. O'Brien T.D., Westermark P., and Johnson K.H. Islet amyloid polypeptide and insulin secretion from isolated perfused pancreas of fed, fasted, glucose-treated, and dexamethasone-treated rats. Diabetes 40 (1991) 1701-1706
97. Ogawa A., Harris V., McCorkle S.K., Unger R.H., and Luskey K.L. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J. Clin. Invest. 85 (1990) 973-976
98. Ohtsuka H., Iwanaga T., Fujino M.A., and Fujita T. Amylin-containing cells in the gastro-entero-pancreatic (GeP) endocrine system of the rat and humans-an immunohistochemical study. Acta Histochem. Cytochem. 26 (1993) 405-414
99. Pacini G., Thomaseth K., Kautzky-Miller A., Clodi M., Waldhäusl W., and Prager R. Islet amyloid polypeptide secretion and kinetics in insulin resistant hypertensive patients. Diabetologia 36 (1993) A136
100. Percy A.J., Trainor D., Rittenhouse J., Janes S., and Koda J.E. Sensitive two-site enzyme immunoassays for amylin and amylin-like peptides in human plasma. Diabetologia 37 (1994) A117
101. Percy A.J., Trainor D.A., Rittenhouse J., Phelps J., and Koda J.E. Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. Clin. Chem. 42 (1996) 576-585
102. Percy A.J., Trainor D., Blase E., Redalieu E., and Koda J.E. Development of a sensitive immunoassay for pramlintide and its use in pharmacokinetic studies. J. Clin. Ligand Assay 20 (1997) 32-39
103. Petry C.J., Percy A., Koda J.E., and Hales C.N. Development of sensitive two-site immunoassays for rat amylin. Proceedings of the ACB National Meeting (1995) 75
104. Pieber T.R., Stein D.T., Ogawa A., Alam T., Ohneda M., Mccorkle K., Chen L., Mcgarry J.D., and Unger R.H. Amylin-insulin relationships in insulin resistance with and without diabetic hyperglycemia. Am. J. Physiol. 265 (1993) E446-E453
105. Pieber T.R., Roitelman J., Lee Y., Luskey K.L., and Stein D.T. Direct plasma radioimmunoassay for rat amylin-(1-37): Concentrations with acquired and genetic obesity. Am. J. Physiol. 267 (1994) E156-E164
106. Rabkin R., and Kitaji J. Renal metabolism of peptide hormones. Miner. Electrolyte Metab. 9 (1983) 212-226
107. Rachman J., Payne M., Levy J., Barrow B., Manley S., Holman R., and Turner R. Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM. Diabetologia 39 (1996) A149
108. Reaven G.M., and Miller R. Study of the relationship between glucose and insulin responses to an oral glucose load in man. Diabetes 17 (1968) 560-569
109. Redalieu E., Thompson R.G., Dean E., Petrella E., Musunuri S., and Gottlieb A. Pharmacokinetics of pramlintide and free insulin following combined or separate injections in patients with type I diabetes. Diabetes 45 (1996) 220A
110. Rittenhouse J., Chait B.T., Bierle J.R., Janes S.M., Park D.R., Phelps J.L., Fineman M.S., Qin J., and Koda J.E. Heterogeneity of naturally-occurring human amylin due to glycosylation. Diabetes 45 (1996) 234A
111. Röcken C., Linke R.P., and Saeger W. Immunohistology of islet amyloid polypeptide in diabetes mellitus: Semi-quantitative studies in a post-mortem series. Virchows Arch. A Pathol. Anat. Histopathol. 421 (1992) 339-344
112. Saad M.F., Knowler W.C., Pettitt D.J., Nelson R.G., Mott D.M., and Bennett P.H. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1 (1989) 1356-1359
113. Sanke T., Bell G.I., Sample C., Rubenstein A.H., and Steiner D.F. An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing. J. Biol. Chem. 263 (1988) 17243-17246
114. Sanke T., Hanabusa T., Nakano Y., Oki C., Okai K., Nishimura S., Kondo M., and Nanjo K. Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34 (1991) 129-132
115. Shiomi K., Nakazato M., Miyazato M., Kangawa K., Matsuo H., and Matsukura S. Establishment of hypersensitive radioimmunoassay for islet amyloid polypeptide using antiserum specific for its N-terminal region. Biochem. Biophys. Res. Commun. 186 (1992) 1065-1073
116. Skofitsch G., Wimalawansa S.J., Jacobowitz D.M., and Gubisch W. Comparative immunohistochemical distribution of amylin-like and calcitonin gene related peptide like immunoreactivity in the rat central nervous system. J. Physiol. Pharmacol. Can. J. Physiol. Pharmacol. 73 (1995) 945-956
117. Smith P., La Chappell R., Blaise E., Gedulin B., Young A., and Vine W. Effects of nephrectomy on amylin action and plasma concentration in rats. Program and Abstracts, 10th International Congress of Endocrinology (1996) 418
118. Stridsberg M., Eriksson B., Lundqvist G., Skogseid B., Wilander E., and Oberg K. Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours. Regul. Pept. 55 (1995) 119-131
119. Swinburn B.A., Gianchandani R., Saad M.F., and Lillioja S. In vivo beta-cell function at the transition to early non-insulin-dependent diabetes mellitus. Metabolism 44 (1995) 757-764
120. Tasaka Y., Nakaya F., Matsumoto H., Iwamoto Y., and Omori Y. Pancreatic amylin content in human diabetic subjects and its relation to diabetes. Pancreas 11 (1995) 303-308
121. Thomaseth K., Kautzky Willer A., Ludvik B., Prager R., and Pacini G. Integrated mathematical model to assess beta-cell activity during the oral glucose test. Am. J. Physiol. 33 (1996) E522-E531
122. Tokuyama Y., Kanatsuka A., Ohsawa H., Yamaguchi T., Makino H., Yoshida S., Nagase H., and Inoue S. Hypersecretion of islet amyloid polypeptide from pancreatic islets of ventromedial hypothalamic-lesioned rats and obese Zucker rats. Endocrinology 128 (1991) 2739-2744
123. Tokuyama Y., Kanatsuka A., Yamaguchi T., Ohsawa H., Makino H., Nishimura M., and Yoshida S. Islet amyloid polypeptide/amylin contents in pancreata increase in genetically obese and diabetic mice. Horm. Metab. Res. 25 (1993) 289-291
124. Tokuyama Y., Kanatsuka A., Suzuki Y., Yamaguchi T., Taira M., Makino H., and Yoshida S. Islet amyloid polypeptide gene: No evidence of abnormal promoter region in thirty-five type 2 diabetic patients. Diabet. Res. Clin. Pract. 22 (1994) 99-105
125. Toshimori H., Narita R., Nakazato M., Asai J., Mitsukawa T., Kangawa K., Matsuo H., and Matsukura S. Islet amyloid polypeptide (IAPP) in the gastrointestinal tract and pancreas of man and rat. Cell Tissue Res. 262 (1990) 401-406
126. Unger R.H., and Foster D.W. Ch 24: Diabetes Mellitus. In: Wilson J.D., and Foster D.W. (Eds). "Williams Textbook of Endocrinology,". 8th ed. (1992), W. B. Saunders, Philadelphia 1273-1275
127. Valdemarsson S., Leckstrom A., Westermark P., and Bergenfelz A. Increased plasma levels of islet amyloid polypeptide in patients with primary hyperparathyroidism. Eur. J. Endocrinol. 134 (1996) 320-325
128. van Hulst K.L., Hackeng W.H.L., Nieuwenhuis M.G., Höppener J.W.M., Blankenstein M.A., and Lips C.J.M. An improved method for the determination of islet amyloid polypeptide in plasma: Levels in diabetic patients. Diabetologia 36 (1993) A137
129. van Hulst K.L., Hackeng W.H., Hoppener J.W., van Jaarsveld B.C., Nieuwenhuis M.G., Blankenstein M.A., and Lips C.J. An improved method for the determination of islet amyloid polypeptide levels in plasma. Ann. Clin. Biochem. 31 Pt 2 (1994) 165-170
130. van Jaarsveld B.C., Hackeng W.H., Lips C.J., and Erkelens D.W. Plasma concentrations of islet amyloid polypeptide after glucagon administration in type 2 diabetic patients and non-diabetic subjects. Diabet. Med. 10 (1993) 327-330
131. Vine W., Smith P., LaChappell R., Blase E., Lawler R., and Young A. Nephrectomy slows clearance of pramlintide and rat amylin in rats. Diabetologia 39 (1996) A235
132. Vine W., Smith P., LaChappell R., Blase E., Percy A., Koda J., and Young A. Plasma amylin concentrations in rats quantified by a monoclonal immunoenzymetric assay. 79th Annual Meeting of the Endocrine Society, Program and Abstracts (1997) 195
133. Vine W., Blase E., Smith P., LaChappell R., Percy A., Koda J., and Young A. Plasma amylin concentrations in rats: Utility of a monoclonal immunoenzymometric assay. Diabetologia 40 (1997) A301
134. Vine W., Smith P., LaChappell R., Blase E., Lumpkin R., and Young A. Nephrectomy decreases amylin and pramlintide clearance in rats. Horm. Metab. Res. 30 (1998) 514-517
135. Wang Y.N., Chang D., and Chang J.K. Co-localization of amylin and insulin immunoreactivities in porcine pancreatic islets. FASEB J. 4 (1990) A402
136. Wareham N.J., Swinn R., Fineman M., Koda J., Taylor K., and O'Rahilly S. The concentration of glycosylated amylin species is increased in women with gestational diabetes mellitus. Diabet. Med. 13 (1996) S44
137. Watschinger B., Hartter E., Traindl O., Pohanka E., Pidlich J., and Kovarik J. Increased levels of plasma amylin in advanced renal failure. Clin. Nephrol. 37 (1992) 131-134
138. Welborn T.A., Breckenridge A., Rubinstein A.H., Dollery C.T., and Fraser T.R. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet 1 (1966) 1336-1337
139. Wood J.M., Mah S.C., and Schnell C. Comparison of the acute hypotensive effects of renin inhibition, converting enzyme inhibition, and angiotensin II antagonism in rats. J. Cardiovasc. Pharmacol. 16 suppl. 4 (1990) S60-S64
140. Young A.A., Rink T.J., and Wang M.W. Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP-alpha) in the fasted, anaesthetized rat. Life Sci. 52 (1993) 1717-1726
141. Young A.A., Gedulin B., Vine W., Percy A., and Rink T.J. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38 (1995) 642-648
142. Young A.A., Vine W., Gedulin B.R., Pittner R., Janes S., Gaeta L.S.L., Percy A., Moore C.X., Koda J.E., Rink T.J., and Beaumont K. Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin. Drug Dev. Res. 37 (1996) 231-248
143. Zweers E.J.K., Bravenboer B., van Hulst K.L., Lips C.J.M., Christiaens G.C.M.L., Hackeng W.H.L., and Erkelens D.W. Glucose stimulated islet amyloid polypeptide and gestational diabetes mellitus. Diabetologia 35 (1992) A179